



David H. Altreuter, PhD
VP CMC
Quiet Therapeutics

Summary: Experienced developer of novel parenteral drug systems, most recently directed project teams and the design of immunomodulatory nanoparticles at Selecta Biosciences. Prior director roles in formulation, processes development, & manufacturing at Alnylam Pharmaceuticals and Acusphere, Inc.

Education: BSE in ChE, Princeton University; PhD in ChE, Univ. of California, Berkeley. Concentration in biotechnology and bioengineering.

Professional profile: Technical expertise in materials and chemical processing technologies has led to leading scientific and management roles in the design, formulation, process development, and manufacturing of injectable particulate drug products. In-depth experience in drug product technologies include: porous polymeric microparticles for ultrasound contrast, rapid dissolution micro and nanoparticles for hydrophobic drug delivery including both amorphous and crystalline API formats, lipid nanoparticles for siRNA delivery, self-assembling polymeric nanoparticles with surface display or internal entrapment of antigens and immune modulators, and hyaluronic acid coated lipid particles. Product development roles have included leading multiple CMC teams through preclinical and early-phase clinical projects, representing and leading teams on regulatory and clinical operations, running collaborative development efforts between biotechnology and large pharma.